Zepbound Approved for Chronic Weight Management
The FDA has approved Zepbound (tirzepatide) for chronic weight management in adults aged 18 years and older.
Source: clinicaladvisor.com
📰 Boxed Warning News
Page 14 - Boxed Warning News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Boxed Warning. Real-time updates on events, politics, business and more.
Natrelle® Unveils New "For Every BODY" Campaign
Refreshed Look Spotlights Most Diverse Breast Implant Portfolio for a Customized Look IRVINE, Calif., Nov. 8, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company , embraces the immensely...
Carrie Strom Instagram Natrellebreastaugmentation Surgeon Data Consumer Market Research Global Allergan Aesthetics Senior Vice President
Source: marketscreener.com
FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems
Adults taking Zepbound in a clinical trial lost on average 48 lb. at the highest dose Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to...
Source: marketscreener.com
Delcath Systems to Host Third Quarter 2023 Results Call
NEW YORK, Nov. 6, 2023 /PRNewswire/ -- Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will...
United States United Kingdom Ben Shamsian Delcath Systems Inc Prnewswire Delcath Systems Inc International Toll
Source: marketscreener.com
Delcath Systems to Host Third Quarter 2023 Results Call
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...
United Kingdom United States Ben Shamsian International Toll Prnewswire Delcath Systems Inc Delcath Systems Inc
Source: prnewswire.com
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
02.11.2023 - ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023. ...
United States Heather Adkins Huet Eli Lilly Company Annual Report On Form American Society Of Hematology Exchange Commission On
Source: wallstreet-online.de
UCB : presents latest data from generalized myasthenia gravis portfolio at 2023 AANEM Annual Meeting and MGFA Scientific Session -November 01, 2023 at 02:03 am EDT
UCB presents latest data from generalized myasthenia gravis portfolio at 2023 AANEM Annual Meeting and MGFA Scientific Session 14 presentations - including 3...
Source: marketscreener.com
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2023 Scientific Meeting
/PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced that three scientific abstracts evaluating...
Source: prnewswire.com
ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the European Medicines Agency has accepted the Marketing...
United States Michael Vasconcelles European Medicines Agency Immunogen Inc American Society Of Clinical Oncology Annual Meeting Marketing Authorization Application
Source: marketscreener.com
DAXXIFY® Becomes First Facial Injectable to be Named to TIME's Best Inventions -October 26, 2023 at 08:10 am EDT
- DAXXIFY® for Injection named to TIME’s list of the best inventions of 2023. - DAXXIFY® is a long-lasting peptide enhanced neuromodulator that delivers the first true innovation in...
Source: marketscreener.com